פרקסיפרין 0.4 מ"ל/ 3800 iu axa
glaxo smith kline (israel) ltd - nadroparin calcium 3800 iu / 0.4 ml - solution for injection - nadroparin - prophylactic treatment of venous thromboembolic disease during surgery for patients presenting with moderate or high risk. treatment of constituted deep vein thrombosis. prevention of coagulation in the extra corporeal circuit during heamodialysis. the prophylaxis of thromboembolic disorders in high risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure) hospitalised in intensive care unit.
פרקסיפרין 0.3 מ"ל / 2850 axa iu
glaxo smith kline (israel) ltd - nadroparin calcium 2850 iu / 0.3 ml - solution for injection - nadroparin - prophylactic treatment of venous thromboembolic disease during surgery for patients presenting with moderate or high risk. treatment of constituted deep vein thrombosis. prevention of coagulation in the extra corporeal circuit during haemodialysis. the prophylaxis of thromboembolic disorders in high risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure) hospitalised in intensive care unit.
פרקסיפרין 0.6 מ"ל/ 5700 iu axa
glaxo smith kline (israel) ltd - nadroparin calcium 5700 iu / 0.6 ml - solution for injection - nadroparin - prophylactic treatment of venous thromboembolic disease during surgery for patients presenting with moderate or high risk. treatment of constituted deep vein thrombosis. prevention of coagulation in the extra corporeal circuit during haemodialysis. the prophylaxis of thromboembolic disorders in high risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure) hospitalised in intensive care unit.
פרקסיפרין 0.8 מ"ל/7600 iu axa
glaxo smith kline (israel) ltd - nadroparin calcium 7600 iu / 0.8 ml - solution for injection - nadroparin - prophylactic treatment of venous thromboembolic disease during surgery for patients presenting with moderate or high risk. treatment of constituted deep vein thrombosis. prevention of coagulation in the extra corporeal circuit during haemodialysis. the prophylaxis of thromboembolic disorders in high risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure) hospitalised in intensive care unit.
קובן
medison pharma ltd - sapropterin dihydrochloride - טבליות מסיסות - sapropterin dihydrochloride 100 mg - sapropterin - sapropterin - kuvan is indicated for the treatment of hyperphenylalaninaemia (hpa) in adult and paediatric patients of 4 years of age and over with phenylketonuria (pku) who have been shown to be responsive to such treatment.kuvan is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adult and paediatric patients with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.
קומדין 1 מג
taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 1 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.
קומדין 2 מג
taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 2 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonar embolism. coumadin is indicated for the prophylaxis and/or treatment of the tromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.
קומדין 2.5 מג
taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 2.5 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.
קומדין 3 מג
taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 3 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.
קומדין 4 מג
taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 4 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.